PTPRG

Across TCGA pan-cancer cohorts, PTPRG Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PTPRG data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher PTPRG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTPRG expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCS, UCEC, and OV are the cancer types where PTPRG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.141	0.698	<.001	48	view →
UCEC	DFS	Median	II,III,IV	0.901	0.297	.004	30	view →
OV	DFS	Median	All	0.264	0.544	.002	26	view →
LUAD	DFS	Median	All	0.423	0.670	.024	10	view →
BLCA	OS	Median	III,IV	0.240	0.549	.024	6	view →
SKCM	OS	Median	III,IV	0.546	0.851	.002	6	view →
SARC	DFS	Median	All	0.155	0.598	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PTPRG–UCS (OS)

Open the UCS breakdown →